Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients 50 years.

565Background: Recent prospective clinical trials have demonstrated a differential chemotherapy effect based on age (≤ 50 vs. > 50 years) or menopausal status (pre- vs. post-) in a genomic low risk...